Retrospective real-world observational study of 4,309 patients initiating tirzepatide through the Juniper digital weight loss service in Australia (September 2024–April 2025), evaluating 6- and 12-month weight loss, adherence rates, and outcome predictors. Provides Australian real-world tirzepatide effectiveness data from a digital health delivery model. Documents tirzepatide effectiveness in the Australian digital health prescribing context—providing the first Australia-specific real-world evidence for a market where digital-first prescribing models are becoming a primary channel for GLP-1/GIP agonist access.
Talay, Louis; Hom, Jason; Scott, Tamara; Ahuja, Neera